EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lexaria Bioscience's Enterprise Value is $27.06 Mil.
Lexaria Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 was $-5.41 Mil. Therefore, Lexaria Bioscience's EV-to-FCF for today is -5.00.
The historical rank and industry rank for Lexaria Bioscience's EV-to-FCF or its related term are showing as below:
LEXX'
s EV-to-FCF Range Over the Past 10 Years
Min: -71.64 Med: -5.58 Max: 132.04
Current: -5
During the past 13 years, the highest EV-to-FCF of Lexaria Bioscience was 132.04. The lowest was -71.64. And the median was -5.58.
LEXX's EV-to-FCF is ranked worse than 100% of 391
companies
in the Biotechnology industry
Industry Median: 4.47
vs LEXX: -5.00
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Lexaria Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lexaria Bioscience's EV-to-FCF
For the Biotechnology subindustry, Lexaria Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's EV-to-FCF falls into.
Lexaria Bioscience's current Enterprise Value is $27.06 Mil.
Lexaria Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Lexaria Bioscience's PE Ratio for today is calculated as:
Lexaria Bioscience's share price for today is $3.09.
Lexaria Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Lexaria Bioscience EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Lexaria Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Lexaria Bioscience (Lexaria Bioscience) Business Description
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEXX has been successfully added to your 